{"id":"https://openalex.org/W4247796277","doi":"https://doi.org/10.1111/j.1365-2125.2008.03158.x","title":"The pharmacokinetics, CNS pharmacodynamics and adverse event profile of brivaracetam after multiple increasing oral doses in healthy men","display_name":"The pharmacokinetics, CNS pharmacodynamics and adverse event profile of brivaracetam after multiple increasing oral doses in healthy men","alternate_titles":[],"publication_year":2008,"publication_date":"2008-05-06","ids":{"openalex":"https://openalex.org/W4247796277","doi":"https://doi.org/10.1111/j.1365-2125.2008.03158.x"},"language":"en","primary_location":{"id":"doi:10.1111/j.1365-2125.2008.03158.x","doi":"https://doi.org/10.1111/j.1365-2125.2008.03158.x","is_oa":false,"landing_page_url":"https://doi.org/10.1111/j.1365-2125.2008.03158.x","pdf_url":null,"source":{"id":"https://openalex.org/S13842274","display_name":"British Journal of Clinical Pharmacology","issn_l":"0306-5251","issn":["0306-5251","1365-2125"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["anvur-scientific","cwts-core","dongbi-b","doyens","jufo-2","ki-jl-2","medline","norway-2","poland-100","russia-white-list-2","vabb-shw"],"host_organization":"https://openalex.org/P4310320595","host_organization_name":"Wiley","host_organization_lineage":["https://openalex.org/P4310320595"],"host_organization_lineage_names":["Wiley"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"British Journal of Clinical Pharmacology","raw_type":"journal-article"},"parent_works":[],"lineage":["https://openalex.org/W4247796277"],"child_works_count":0,"type":"article","is_traditional":true,"indexed_in":["crossref"],"open_access":{"is_oa":false,"oa_status":"closed","oa_url":null,"any_repository_has_fulltext":false},"authorships":[{"author_position":"first","author":{"id":"https://openalex.org/A5040398083","display_name":"Paul Edward Rolan","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I85722119","display_name":"UCB Pharma (Belgium)","ror":"https://ror.org/01n029866","country_code":"BE","type":"company","lineage":["https://openalex.org/I85722119"]}],"countries":["BE"],"is_corresponding":false,"contributor_roles":[],"raw_author_name":"Paul Rolan","raw_affiliation_strings":["Medeval Ltd, Manchester, UK","Medeval Ltd, Manchester, UK and UCB Pharma S.A., Global Exploratory Development, Braine-l'Alleud, Belgium"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Medeval Ltd, Manchester, UK","institution_ids":[]},{"raw_affiliation_string":"Medeval Ltd, Manchester, UK and UCB Pharma S.A., Global Exploratory Development, Braine-l'Alleud, Belgium","institution_ids":["https://openalex.org/I85722119"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5072004843","display_name":"Maria Laura Sargentini\u2010Maier","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I85722119","display_name":"UCB Pharma (Belgium)","ror":"https://ror.org/01n029866","country_code":"BE","type":"company","lineage":["https://openalex.org/I85722119"]}],"countries":["BE"],"is_corresponding":true,"contributor_roles":[],"raw_author_name":"Maria Laura Sargentini\u2010Maier","raw_affiliation_strings":["Medeval Ltd, Manchester, UK and UCB Pharma S.A., Global Exploratory Development, Braine-l'Alleud, Belgium"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Medeval Ltd, Manchester, UK and UCB Pharma S.A., Global Exploratory Development, Braine-l'Alleud, Belgium","institution_ids":["https://openalex.org/I85722119"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5031583416","display_name":"Etienne Pigeolet","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I85722119","display_name":"UCB Pharma (Belgium)","ror":"https://ror.org/01n029866","country_code":"BE","type":"company","lineage":["https://openalex.org/I85722119"]}],"countries":["BE"],"is_corresponding":false,"contributor_roles":[],"raw_author_name":"Etienne Pigeolet","raw_affiliation_strings":["Medeval Ltd, Manchester, UK and UCB Pharma S.A., Global Exploratory Development, Braine-l'Alleud, Belgium"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Medeval Ltd, Manchester, UK and UCB Pharma S.A., Global Exploratory Development, Braine-l'Alleud, Belgium","institution_ids":["https://openalex.org/I85722119"]}]},{"author_position":"last","author":{"id":"https://openalex.org/A5042643544","display_name":"Armel Stockis","orcid":"https://orcid.org/0000-0002-0815-5264","observed_orcids":["https://orcid.org/0000-0002-0815-5264"]},"institutions":[{"id":"https://openalex.org/I85722119","display_name":"UCB Pharma (Belgium)","ror":"https://ror.org/01n029866","country_code":"BE","type":"company","lineage":["https://openalex.org/I85722119"]}],"countries":["BE"],"is_corresponding":false,"contributor_roles":[],"raw_author_name":"Armel Stockis","raw_affiliation_strings":["Medeval Ltd, Manchester, UK and UCB Pharma S.A., Global Exploratory Development, Braine-l'Alleud, Belgium"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Medeval Ltd, Manchester, UK and UCB Pharma S.A., Global Exploratory Development, Braine-l'Alleud, Belgium","institution_ids":["https://openalex.org/I85722119"]}]}],"institutions":[],"countries_distinct_count":1,"institutions_distinct_count":1,"corresponding_author_ids":["https://openalex.org/A5072004843"],"corresponding_institution_ids":["https://openalex.org/I85722119"],"apc_list":{"value":4780,"currency":"USD","value_usd":4780},"apc_paid":null,"fwci":3.8655,"has_fulltext":false,"cited_by_count":129,"reviewed_by_count":0,"citation_normalized_percentile":{"value":0.93272434,"is_in_top_1_percent":false,"is_in_top_10_percent":true},"cited_by_percentile_year":{"min":94,"max":99},"biblio":{"volume":"66","issue":"1","first_page":"71","last_page":"75"},"is_retracted":false,"is_pulled":false,"is_paratext":false,"is_xpac":false,"primary_topic":{"id":"https://openalex.org/T10094","display_name":"Epilepsy research and treatment","score":0.9843999743461609,"subfield":{"id":"https://openalex.org/subfields/2728","display_name":"Clinical Neurology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},"topics":[{"id":"https://openalex.org/T10094","display_name":"Epilepsy research and treatment","score":0.9843999743461609,"subfield":{"id":"https://openalex.org/subfields/2728","display_name":"Clinical Neurology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T12229","display_name":"Pharmacological Effects and Toxicity Studies","score":0.00930000003427267,"subfield":{"id":"https://openalex.org/subfields/2735","display_name":"Pediatrics, Perinatology and Child Health"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T10077","display_name":"Neuroscience and Neuropharmacology Research","score":0.0017999999690800905,"subfield":{"id":"https://openalex.org/subfields/2804","display_name":"Cellular and Molecular Neuroscience"},"field":{"id":"https://openalex.org/fields/28","display_name":"Neuroscience"},"domain":{"id":"https://openalex.org/domains/1","display_name":"Life Sciences"}}],"keywords":[{"id":"https://openalex.org/keywords/brivaracetam","display_name":"brivaracetam","score":1.0},{"id":"https://openalex.org/keywords/pharmacokinetics","display_name":"pharmacokinetics","score":0.9879999756813049},{"id":"https://openalex.org/keywords/adverse-events","display_name":"adverse events","score":0.6800000071525574},{"id":"https://openalex.org/keywords/multiple-oral-doses","display_name":"multiple oral doses","score":0.7459999918937683},{"id":"https://openalex.org/keywords/healthy-volunteers","display_name":"healthy volunteers","score":0.6190000176429749},{"id":"https://openalex.org/keywords/dose-proportionality","display_name":"dose proportionality","score":0.7129999995231628},{"id":"https://openalex.org/keywords/drug-metabolism","display_name":"drug metabolism","score":0.5910000205039978},{"id":"https://openalex.org/keywords/cyp3a4-induction","display_name":"CYP3A4 induction","score":0.847000002861023},{"id":"https://openalex.org/keywords/sedation","display_name":"sedation","score":0.5889999866485596},{"id":"https://openalex.org/keywords/drug-tolerability","display_name":"drug tolerability","score":0.5090000033378601}],"concepts":[{"id":"https://openalex.org/C112705442","wikidata":"https://www.wikidata.org/wiki/Q323936","display_name":"Pharmacokinetics","level":2,"score":0.8776077032089233},{"id":"https://openalex.org/C111113717","wikidata":"https://www.wikidata.org/wiki/Q725307","display_name":"Pharmacodynamics","level":3,"score":0.7625558376312256},{"id":"https://openalex.org/C98274493","wikidata":"https://www.wikidata.org/wiki/Q128406","display_name":"Pharmacology","level":1,"score":0.7081916928291321},{"id":"https://openalex.org/C2778375690","wikidata":"https://www.wikidata.org/wiki/Q7814214","display_name":"Tolerability","level":3,"score":0.5976775884628296},{"id":"https://openalex.org/C71924100","wikidata":"https://www.wikidata.org/wiki/Q11190","display_name":"Medicine","level":0,"score":0.5709332227706909},{"id":"https://openalex.org/C197934379","wikidata":"https://www.wikidata.org/wiki/Q2047938","display_name":"Adverse effect","level":2,"score":0.5436384677886963},{"id":"https://openalex.org/C139254425","wikidata":"https://www.wikidata.org/wiki/Q1332167","display_name":"Volume of distribution","level":3,"score":0.4772738814353943},{"id":"https://openalex.org/C87813604","wikidata":"https://www.wikidata.org/wiki/Q1242899","display_name":"Crossover study","level":4,"score":0.47504591941833496},{"id":"https://openalex.org/C2778186239","wikidata":"https://www.wikidata.org/wiki/Q41571","display_name":"Epilepsy","level":2,"score":0.4413033425807953},{"id":"https://openalex.org/C2780026642","wikidata":"https://www.wikidata.org/wiki/Q40924","display_name":"Urine","level":2,"score":0.44019991159439087},{"id":"https://openalex.org/C27081682","wikidata":"https://www.wikidata.org/wiki/Q269829","display_name":"Placebo","level":3,"score":0.2962642312049866},{"id":"https://openalex.org/C126322002","wikidata":"https://www.wikidata.org/wiki/Q11180","display_name":"Internal medicine","level":1,"score":0.2538294196128845},{"id":"https://openalex.org/C142724271","wikidata":"https://www.wikidata.org/wiki/Q7208","display_name":"Pathology","level":1,"score":0.06495210528373718},{"id":"https://openalex.org/C118552586","wikidata":"https://www.wikidata.org/wiki/Q7867","display_name":"Psychiatry","level":1,"score":0.0},{"id":"https://openalex.org/C204787440","wikidata":"https://www.wikidata.org/wiki/Q188504","display_name":"Alternative medicine","level":2,"score":0.0}],"mesh":[],"locations_count":2,"locations":[{"id":"doi:10.1111/j.1365-2125.2008.03158.x","doi":"https://doi.org/10.1111/j.1365-2125.2008.03158.x","is_oa":false,"landing_page_url":"https://doi.org/10.1111/j.1365-2125.2008.03158.x","pdf_url":null,"source":{"id":"https://openalex.org/S13842274","display_name":"British Journal of Clinical Pharmacology","issn_l":"0306-5251","issn":["0306-5251","1365-2125"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["anvur-scientific","cwts-core","dongbi-b","doyens","jufo-2","ki-jl-2","medline","norway-2","poland-100","russia-white-list-2","vabb-shw"],"host_organization":"https://openalex.org/P4310320595","host_organization_name":"Wiley","host_organization_lineage":["https://openalex.org/P4310320595"],"host_organization_lineage_names":["Wiley"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"British Journal of Clinical Pharmacology","raw_type":"journal-article"},{"id":"pmh:oai:digital.library.adelaide.edu.au:2440/53482","doi":null,"is_oa":false,"landing_page_url":"http://hdl.handle.net/2440/53482","pdf_url":null,"source":{"id":"https://openalex.org/S4306401835","display_name":"Adelaide Research & Scholarship (AR&S) (University of Adelaide)","issn_l":null,"issn":null,"is_oa":false,"is_in_doaj":false,"is_core":false,"listed_in":[],"host_organization":"https://openalex.org/I5681781","host_organization_name":"The University of Adelaide","host_organization_lineage":["https://openalex.org/I5681781"],"host_organization_lineage_names":[],"type":"repository"},"license":null,"license_id":null,"version":"submittedVersion","is_accepted":false,"is_published":false,"raw_source_name":"https://doi.org/10.1111/j.1365-2125.2008.03158.x","raw_type":"Journal article"}],"best_oa_location":null,"sustainable_development_goals":[{"display_name":"Good health and well-being","score":0.9940000176429749,"id":"https://metadata.un.org/sdg/3"}],"study_designs":[],"awards":[],"funders":[],"has_content":{"pdf":false,"grobid_xml":false},"content_urls":null,"referenced_works_count":9,"referenced_works":["https://openalex.org/W2018622804","https://openalex.org/W2037616672","https://openalex.org/W2043288745","https://openalex.org/W2061209838","https://openalex.org/W2066303030","https://openalex.org/W2080215367","https://openalex.org/W2096266931","https://openalex.org/W2127801604","https://openalex.org/W2142051176"],"related_works":["https://openalex.org/W2037616672","https://openalex.org/W2783522776","https://openalex.org/W4213431706","https://openalex.org/W2052474013","https://openalex.org/W2394919271","https://openalex.org/W2462522387","https://openalex.org/W2181380452","https://openalex.org/W4280572949","https://openalex.org/W2486400388","https://openalex.org/W4389322841"],"abstract_inverted_index":{"WHAT":[0,53],"IS":[1],"ALREADY":[2],"KNOWN":[3],"ABOUT":[4],"THIS":[5,54],"SUBJECT":[6],"\u2022":[7,26,57],"The":[8],"pharmacokinetic":[9,298],"profile,":[10],"metabolism":[11],"and":[12,39,43,64,101,160,213,230,258,318],"proof":[13],"of":[14,16,21,47,90,105,109,119,166,178,191,207,209,236,279,308],"concept":[15],"a":[17,75,296],"single":[18],"oral":[19,107],"dose":[20,180,292,319],"brivaracetam":[22,110,126,215],"have":[23,29],"been":[24],"reported.":[25],"Previous":[27],"studies":[28],"shown":[30,84],"that":[31,82,261],"it":[32],"was":[33,40,155,168,182,204,270],"well":[34,41,135,271,286],"absorbed,":[35],"had":[36,295],"linear":[37],"kinetics":[38],"tolerated,":[42],"suggested":[44],"effective":[45,291],"doses":[46,108,134,278],"10\u201380":[48],"mg":[49,131,266,281],"in":[50,66,87,111,146,185,201,244,300],"photoparoxysmal":[51],"epilepsy.":[52,91],"STUDY":[55],"ADDS":[56],"We":[58],"now":[59],"report":[60],"the":[61,95,137,179,233,288],"pharmacokinetics,":[62,96],"pharmacodynamics":[63,100],"tolerability":[65],"healthy":[67,112,121,274],"volunteers":[68,276],"after":[69],"multiple":[70,106],"doses.":[71],"AIMS":[72],"Brivaracetam":[73,154,269,294],"is":[74],"novel":[76],"synaptic":[77],"vesicle":[78],"protein":[79],"2A":[80],"ligand":[81],"has":[83],"potent":[85],"activity":[86],"animal":[88],"models":[89],"This":[92],"study":[93],"examined":[94],"central":[97,227],"nervous":[98,228],"system":[99],"adverse":[102],"event":[103],"profile":[104,299],"male":[113,122,275],"subjects.":[114],"METHODS":[115],"Three":[116],"successive":[117],"panels":[118],"12":[120],"subjects":[123],"received":[124],"double\u2010blind":[125],"200,":[127],"400":[128],"or":[129,141,251],"800":[130,265],"day\u22121":[132],"(all":[133],"above":[136,287],"expected":[138,289],"therapeutic":[139],"range)":[140],"placebo":[142],"(9":[143],":":[144],"3),":[145],"two":[147],"divided":[148],"doses,":[149],"for":[150,283],"14":[151],"days.":[152],"RESULTS":[153],"rapidly":[156],"absorbed":[157],"(tmax\u223c2":[158],"h)":[159],"eliminated":[161],"(t1/2":[162],"7\u20138":[163],"h).":[164],"Volume":[165],"distribution":[167,309],"slightly":[169],"lower":[170],"than":[171],"total":[172,312],"body":[173,313],"water.":[174],"A":[175],"small":[176],"fraction":[177],"(5\u20138%)":[181],"excreted":[183],"unchanged":[184],"urine":[186],"together":[187],"with":[188],"significant":[189],"levels":[190,216],"metabolites,":[192],"suggesting":[193],"predominantly":[194],"metabolic":[195],"clearance.":[196],"Based":[197],"on":[198],"6\u2010\u03b2\u2010hydroxycortisol/cortisol":[199],"ratios":[200],"urine,":[202],"there":[203],"no":[205],"evidence":[206],"induction":[208],"CYP3A4":[210],"activity.":[211],"Saliva":[212],"plasma":[214],"were":[217,222,242],"highly":[218],"correlated.":[219],"Adverse":[220],"events":[221],"mostly":[223],"mild":[224],"to":[225,311],"moderate,":[226],"system\u2010related":[229],"resolved":[231],"within":[232],"first":[234],"day":[235],"treatment.":[237],"No":[238],"clinically":[239,290],"relevant":[240],"changes":[241],"observed":[243],"laboratory":[245],"tests,":[246],"vital":[247],"signs,":[248],"physical":[249],"examinations":[250],"ECGs.":[252],"Pharmacodynamic":[253],"tests":[254],"showed":[255],"dose\u2010related":[256],"sedation":[257],"decreased":[259],"alertness":[260],"only":[262],"persisted":[263],"at":[264,277],"daily.":[267],"CONCLUSIONS":[268],"tolerated":[272],"by":[273,304],"200\u2013800":[280],"daily":[282],"2":[284],"weeks,":[285],"range.":[293],"favourable":[297],"this":[301],"population,":[302],"characterized":[303],"rapid":[305],"absorption,":[306],"volume":[307],"limited":[310],"water,":[314],"apparent":[315],"single\u2010compartment":[316],"elimination":[317],"proportionality.":[320]},"cited_by_api_url":"https://api.openalex.org/works?filter=cites:W4247796277","counts_by_year":[{"year":2026,"cited_by_count":4},{"year":2025,"cited_by_count":5},{"year":2024,"cited_by_count":9},{"year":2023,"cited_by_count":8},{"year":2022,"cited_by_count":3},{"year":2021,"cited_by_count":6},{"year":2020,"cited_by_count":11},{"year":2019,"cited_by_count":9},{"year":2018,"cited_by_count":9},{"year":2017,"cited_by_count":9},{"year":2016,"cited_by_count":15},{"year":2015,"cited_by_count":10},{"year":2014,"cited_by_count":4},{"year":2013,"cited_by_count":4},{"year":2012,"cited_by_count":4}],"updated_date":"2026-11-20T13:11:24.684918","created_date":"2022-05-12T00:00:00"}
